The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Comparison Chart: Some Drugs for HFrEF
Download PDF:   US English
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15   doi:10.58347/tml.2025.1729b
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Michael Viscusi, Pharm.D., Associate Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Explain the current approach to the management of chronic heart failure.
  2. Discuss the pharmacologic options available for treatment of chronic heart failure and compare them based on their mechanism of action, efficacy, and potential adverse effects.
  3. Determine the most appropriate pharmacologic treatment for chronic heart failure with reduced ejection fraction for an individual patient.
 Select a term to see related articles     Accupril   ACE inhibitors   Aldactone   Altace   ARBs   Atacand   beta blockers   BiDil   bisoprolol   bumetanide   Burinex   candesartan   captopril   Carospir   carvedilol   Corlanor   Coversyl   Cozaar   dapagliflozin   digoxin   Diovan   diuretics   empagliflozin   enalapril   Entresto   eplerenone   Farxiga   finerenone   Forxiga   furosemide   heart failure   hydralazine   Inpefa   Inspra   isosorbide dinitrate   ivabradine   Jardiance   Kapspargo Sprinkle   Kerendia   Lancora   Lasix   lisinopril   losartan   Mavik   metoprolol   Noyada   quinapril   ramipril   sacubitril   sotagliflozin   spironolactone   Toprol   torsemide   trandolapril   valsartan   Vasotec   vericiguat   Verquvo   Zestril 

View the Comparison Chart: Some Drugs for HFrEF

Download PDF: US English

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article